EC Approves Teva's Generic Version Of Neupogen

Law360, New York (September 16, 2008, 12:00 AM EDT) -- In a still relatively rare approval of a biosimilar drug, Israeli generic-drug maker Teva Pharmaceutical Industries Ltd. announced Tuesday that the European Commission had approved a copycat version of Amgen Inc.'s neutropenia treatment Neupogen.

Teva's human granulocyte colony stimulating factor, or G-CSF, product is the first biosimilar G-CSF to receive a marketing authorization by the EC, according to the company.

The EC's approval reportedly comes just a few months after the scientific committee of the European Medicines Evaluation Agency issued a positive opinion for the product....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.